Presentations and Posters
Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03)
Kazutaka Narui, Toshinari Yamashita, Masahiro Kitada, Hidetoshi Kawaguchi, Masaya Hattori, Tetsuhiro Yoshinami, Nobuki Matsunami, Kazuhiro Yanagihara, Teru Kawasoe, Takeshi Nagashima, Hiroko Bando, Hiroshi Yano, Yoshie Hasegawa, Rikiya Nakamura, Masahiro Kashiwaba, Norikazu Masuda, Satoshi Morita, Shinji Ohno, Masakazu Toi
2017年6月 ASCO Poster Chicago
Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from JBCRG-16/Neo-LaTH
Moe Tsuda, Hiroshi Ishiguro, Naoko Toriguchi, Norikazu Masuda, Hiroko Bando, Oogami Masahiro, Honma Masato, Satoru Shimizu, Naohito Yamamoto, Katsumasa Kuroi, Yasuhiro Yanagita, Toshimi Takano, Satoshi Morita, Masakazu Toi
2016.12 SABCS Poster San Antonio, Texas
Analysis of tumor infiltrating lymphocytes in HER2-positive primary breast cancer treated with neoadjuvant lapatinib and trastuzumab: The NeoLath study (JBCRG-16)
Kosuke Kawaguchi, Eiji Suzuki, Tatsuki R Kataoka, Masahiro Hirata, Shinji Ohno, Hiroko Bando, Hiroshi Ishiguro, Kenichi Inoue, Naohito Yamamoto, Katsumasa Kuroi, Satoshi Morita, Norikazu Masuda, Masakazu Toi, Japan Breast Cancer Research Group (JBCRG)
2016 ASCO Poster
PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy (JBCRG-M05)
Yutaka Yamamoto, Hiroji Iwata, Takayuki Ueno, Masahiro Kashiwaba, Naruto Taira, Masato Takahashi, Hiroshi Tada, Koichiro Tsugawa, Tatsuya Toyama, Naoki Niikura, Fumitaka Hara, Tomomi Fujisawa, Tetsuhiro Yoshinami, Shigehira Saji, Toshimi Takano, Norikazu Masuda, Satoshi Morita, Masakazu Toi, Shinji Ohno
2016 ASCO Poster
Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17)
Naoto Kondo, Yoshinori Ito, Ippei Fukada, Shoichiro Ohtani, Masaya Hattori, Eriko Tokunaga, Nobuki Matsunami, Kohjiro Mashino, Taijiro Kosaka, Masahiko Tanabe, Daisuke Yotsumoto, Kosho Yamanouchi, Masataka Sawaki, Masahiro Kashiwaba, Hidetaka Kawabata, Katsumasa Kuroi, Satoshi Morita, Shinji Ohno, Masakazu Toi, Norikazu Masuda
2016 ASCO Poster
Search for appropriate treatment strategy using fulvestrant for postmenopausal ER-positive advanced or recurrent breast cancer patients in Japan (JBCRG-C06; Safari)
Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Yutaka Yamamoto, Shinji Ohno, Masakazu Toi
EBCC, 2016 Mar, Amsterdam, Holland (Poster)
Prospective observational cohort study of bevacizumab combined with paclitaxel as the first- or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE)
Naoto Kondo, Yutaka Yamamoto, Hiroyasu Yamashiro, Masahiro Kashiwaba, Rikiya Nakamura, Masato Takahashi, Uhi Toh, Koichiro Tsugawa, Kazutaka Narui, Kentaro Tamaki, Tetsuhiro Yoshinami, Shoichiro Ohtani, Yuichiro Kai, Toshimi Takano, Yasuhiro Yanagita, Satoshi Morita, Masakazu Toi, Shinji Ohno
EBCC, 2016 Mar, Amsterdam, Holland(Poster)
Pharmacogenomics-pharmacokinetics study of selective estrogen-receptor modulators with intra-patient dose-escalation for Japanese breast cancer patients (JBCRG-12,15)
Shinji Ohno, Hiroshi Ishiguro, Yutaka Yamamoto, Shintaro Takao, Nobuaki Sato, Tomomi Fujisawa, Takayuki Kadoya, Katsumasa Kuroi, Hiroko Bando, Yasufumi Teramura, Hiroji Iwata, Shiro Tanaka, Masakazu Toi
2015 SABCS Poster
Phase Ib dose-escalation study of eribulin plus capecitabine in metastatic breast cancer (JBCRG-18Cape)
Hiroshi Ishiguro, Norikazu Masuda, Hiroyuki Yasojima, Shoichiro Ohtani, Akiyo Yoshimura, Masaya Hattori, Hiroji Iwata
第53回日本癌治療学会学術集会, 2015 Oct, Kyoto Japan (ポスター)
Phase Ib dose-escalation study of Eribulin (Eri) in combination with Gemcitabine (GEM) in patients (pts) with metastatic breast cancer (MBC) (JBCRG-18Gem)
Masahiro Kashiwaba, Risa Goto, Naoto Kondo, Masaya Hattori, Hiroji Iwata
第53回日本癌治療学会学術集会, 2015 Oct, Kyoto Japan (FACO International Workshop 口演)
by Voluntary Organization JBCRG